Format

Send to

Choose Destination
Cancer Res Treat. 2019 Mar 25. doi: 10.4143/crt.2019.086. [Epub ahead of print]

Bevacizumab Plus Erlotinib Combination Therapy for Advanced Hereditary Leiomyomatosis and Renal Cell Carcinoma-Associated Renal Cell Carcinoma: A Multicenter Retrospective Analysis in Korean Patients.

Author information

1
Division of Medical Oncology, Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea.
2
Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
3
Division of Hematology and Medical Oncology, Dongguk University Ilsan Hospital, Ilsan, Korea.
4
Department of Internal Medicine, Konyang University Hospital, Daejeon, Korea.
5
Department of Laboratory Medicine, Gachon University Gil Medical Center, Incheon, Korea.
6
Division of Medical Oncology, Department of Internal Medicine, Gachon University Gil Medical Center, Incheon, Korea.

Abstract

Purpose:

Hereditary leiomyomatosis and renal cell carcinoma (HLRCC) is a rare genetic syndrome resulting from germline mutations in fumarate hydratase. The combination of bevacizumab plus erlotinib showed promising interim results for HLRCC-associated RCC. Based on these results, we analyzed the outcome of bevacizumab plus erlotinib in Korean patients with HLRCC-associated RCC.

Materials and Methods:

We retrospectively reviewed the efficacy and safety of bevacizumab plus erlotinib in patients with HLRCC-associated RCC who were confirmed to have germline mutations in fumarate hydratase. The primary endpoint was the objective response rate (ORR), while the secondary endpoints were progression-free survival (PFS) and overall survival (OS).

Result:

We identified 10 patients with advanced HLRCC-associated RCC who received bevacizumab plus erlotinib. Median age at diagnosis was 41 years, and five of the patients had received the combination as first- or second-line treatments. The ORR was 50% and the median PFS and OS were 13.3 and 14.1 months, respectively. Most adverse events were predictable and manageable by conventional measures, except for one instance where a patient died of gastrointestinal bleeding.

Conclusion:

This is the first real-world outcome of the treatment of advanced HLRCC-associated RCC. Bevacizumab plus erlotinib therapy showed promising activity with moderate toxicity. We should be increasingly aware of HLRCC-associated RCC and bevacizumab plus erlotinib should be a first-line treatment for this condition, unless other promising data are published.

KEYWORDS:

Bevacizumab; Erlotinib; Fumarate hydratase; Hereditary leiomyomatosis and renal cell carcinoma; Non-clear cell; Renal cell carcinoma

PMID:
30913859
DOI:
10.4143/crt.2019.086
Free full text

Supplemental Content

Full text links

Icon for Publishing M2Community
Loading ...
Support Center